Format

Send to

Choose Destination
Eur J Pharmacol. 2017 Dec 15;817:86-95. doi: 10.1016/j.ejphar.2017.05.042. Epub 2017 May 23.

The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies.

Author information

1
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
2
Department of Internal Medicine, Division of Gastroenterology, Rush University Medical Center, 1725 West Harrison Street Chicago, IL 60612, USA.
3
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; Nutricia Research, Uppsalalaan 12, 3584 CT Utrecht, The Netherlands.
4
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands; Department of Internal Medicine, Division of Gastroenterology, Rush University Medical Center, 1725 West Harrison Street Chicago, IL 60612, USA.
5
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. Electronic address: A.D.Kraneveld@uu.nl.

Abstract

Parkinson's disease (PD) is usually characterized by cardinal motor impairments. However, a range of non-motor symptoms precede the motor-phase and are major determinants for the quality of life. To date, no disease modifying treatment is available for PD patients. The gold standard therapy of levodopa is based on restoring dopaminergic neurotransmission, thereby alleviating motor symptoms, whereas non-motor symptoms remain undertreated. One of the most common non-motor symptoms is gastrointestinal dysfunction usually associated with alpha-synuclein accumulations and low-grade mucosal inflammation in the enteric nervous system. Accumulating evidence suggest that the enteric nervous system is involved in PD pathological progression towards the central nervous system. Moreover, different components of the gut could provide a central role in the gut-brain axis, which is as a bidirectional communicational system between the gastrointestinal tract and central nervous system. Dietary components might influence the gut-brain axis by altering microbiota composition or by affecting neuronal functioning in both the ENS and the CNS. This review gives a comprehensive overview of the evidences supporting the hypothesis that PD could initiate in the gut. We also consider how food-based therapies might then have an impact on PD pathology and/or improve non-motor as well as motor symptoms in PD.

KEYWORDS:

Alpha-synuclein; Enteric nervous system; Food-based therapies; Gastrointestinal dysfunction; Microbiota; Parkinson's disease

PMID:
28549787
DOI:
10.1016/j.ejphar.2017.05.042
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center